In addition, since increased brain CD33 expression is associated with higher amyloid plaque load, Gu et al. (2022) used a Mendelian randomization approach to show that CD33 levels on CD66b++ myeloid cells in peripheral blood are associated with a high risk of AD, a finding that our study also confirmed. This evidence concerns the gene CD33 and Alzheimer disease.